HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Armitage, J. M. Articles by Starzl, T. E. Search for Related Content PubMed PubMed Citation Articles by Armitage, J. M. Articles by Starzl, T. E.

The Annals of Thoracic Surgery, Vol 54, 205-210, Copyright © 1992 by The Society of Thoracic Surgeons

ARTICLES

Clinical trial of FK 506 immunosuppression in adult cardiac transplantation

JM Armitage, RL Kormos, S Morita, J Fung, GC Marrone, RL Hardesty, BP Griffith and TE Starzl
Department of Surgery, University of Pittsburgh School of Medicine, Pennsylvania 15261.

The new immunosuppressive agent FK 506 was used as primary immunotherapy in conjunction with low-dose steroids and azathioprine in 72 patients subsequent to orthotopic cardiac transplantation. Overall patient survival at a mean follow-up of 360 days was 92%. The number of episodes of cardiac rejection (grade 3A or greater) within 90 days of transplantation was 0.95 per patient. The actuarial freedom from rejection at 90 days was 41%. Achievement of this level of immunosuppression is comparable with that of cyclosporine-based triple- drug therapy with OKT3 immunoprophylaxis. Thirty percent of patients were tapered off all steroids, and the average steroid dose in the group who received steroids was 8.6 mg of prednisone per day. The incidence of infection reflected the diminished necessity for steroids: seven major infections (10%) and 11 minor infections (16%). Renal dysfunction occurred during the perioperative period in most patients in this trial. However, the incidence of hypertension was 54% compared with 70% during the cyclosporine era. Ten adults underwent successful rescue therapy with FK 506 after cardiac rejection refractory to conventional immunotherapy. Side effects of FK 506 were notably few, and the results of the trial are encouraging for the future of the cardiac transplant recipient.

This article has been cited by other articles:

				V. M. Montori, A. Basu, P. J. Erwin, J. A. Velosa, S. E. Gabriel, and Y. C. Kudva Posttransplantation Diabetes: A systematic review of the literature Diabetes Care, March 1, 2002; 25(3): 583 - 592. [Abstract] [Full Text] [PDF]

				M. De Bonis, L. Reynolds, J. Barros, and B. P. Madden Tacrolimus as a rescue immunosuppressant after heart transplantation Eur. J. Cardiothorac. Surg., May 1, 2001; 19(5): 690 - 695. [Abstract] [Full Text] [PDF]

				S. M. Pham, R. L. Kormos, B. G. Hattler, A. Kawai, A. C. Tsamandas, A. J. Demetris, S. Murali, F. J. Fricker, H. C. Chang, A. B. Jain, et al. A PROSPECTIVE TRIAL OF TACROLIMUS (FK 506) IN CLINICAL HEART TRANSPLANTATION: INTERMEDIATE-TERM RESULTS J. Thorac. Cardiovasc. Surg., April 1, 1996; 111(4): 764 - 772. [Abstract] [Full Text]

				S. M. Pham, R. L. Kormos, R. J. Landreneau, A. Kawai, I. Gonzalez-Cancel, R. L. Hardesty, B. G. Hattler, and B. P. Griffith Solid Tumors After Heart Transplantation: Lethality of Lung Cancer Ann. Thorac. Surg., December 1, 1995; 60(6): 1623 - 1626. [Abstract] [Full Text]

				S. M. Pham, R. J. Keenan, A. S. Rao, P. A. Fontes, R. L. Kormos, K. Abu-Elmagd, A. Zeevi, A. Kawai, B. G. Hattler, R. L. Hardesty, et al. Perioperative Donor Bone Marrow Infusion Augments Chimerism in Heart and Lung Transplant Recipients Ann. Thorac. Surg., October 1, 1995; 60(4): 1015 - 1020. [Abstract] [Full Text]

				R. M. Bolman III Advantage-FK 506: Reduced Chronic Rejection for Lung Transplant Recipients Ann. Thorac. Surg., September 1, 1995; 60(3): 495 - 496. [Full Text]

				R. J. Keenan, H. Konishi, A. Kawai, I. L. Paradis, D. R. Nunley, A. T. Iacono, R. L. Hardesty, R. J. Weyant, and B. P. Griffith Clinical Trial of Tacrolimus Versus Cyclosporine in Lung Transplantation Ann. Thorac. Surg., September 1, 1995; 60(3): 580 - 584. [Abstract] [Full Text]

				S. O. Marx, T. Jayaraman, L. O. Go, and A. R. Marks Rapamycin-FKBP Inhibits Cell Cycle Regulators of Proliferation in Vascular Smooth Muscle Cells Circ. Res., March 1, 1995; 76(3): 412 - 417. [Abstract] [Full Text]